SCHEMBL15480425

SCHEMBL15480425

O=C(CCCCCCC(=O)Nc1cc(F)ccc1F)NO

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 15/20 0.63
HDAC3 O15379 13/20 0.63
HDAC2 Q92769 11/20 0.63
HDAC6 Q9UBN7 11/20 0.63
HDAC10 Q969S8 8/20 0.56
NCOR2 Q9Y618 2/20 0.56
POLB P06746 2/20 0.55
ALDH1A1 P00352 1/20 0.55
GRK2 P25098 1/20 0.55
CTDSP1 Q9GZU7 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.53
HDAC8 Q9BY41 10/20 0.53
HDAC4 P56524 8/20 0.53
HDAC7 Q8WUI4 8/20 0.53
HDAC11 Q96DB2 8/20 0.53
HDAC9 Q9UKV0 8/20 0.53
HDAC5 Q9UQL6 8/20 0.53
EGFR P00533 4/20 0.53
PKM P14618 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15480422 0.88 HDAC1 (0.63) HDAC1HDAC3HDAC2HDAC6HDAC10
SCHEMBL15480418 0.83 HDAC1 (0.56) HDAC1HDAC3HDAC2HDAC6HDAC10
SCHEMBL8363038 0.81 HDAC1 (0.72) HDAC1HDAC3HDAC2HDAC6HDAC10
SCHEMBL15480431 0.81 POLB (0.66) HDAC1HDAC3HDAC2HDAC6NCOR2
SCHEMBL3078183 0.81 SMN1; SMN2 (0.58) POLBALDH1A1GRK2CTDSP1L3MBTL1
SCHEMBL19002811 0.80 SMN1; SMN2 (0.57) POLBALDH1A1GRK2CTDSP1L3MBTL1
SCHEMBL31635252 0.78 HDAC1 (0.62) HDAC1HDAC3HDAC2HDAC6HDAC10
SCHEMBL7929398 0.78 HDAC1 (0.74) HDAC1HDAC3HDAC2HDAC6HDAC10
SCHEMBL4133118 0.78 POLB (0.58) HDAC1HDAC3POLBL3MBTL1PKM
SCHEMBL11939633 0.78 HDAC1 (1.00) HDAC1HDAC3HDAC2HDAC6HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB (SE) 2021-03-04 US disclosed
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENT AB (SE) 2017-01-26 US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC3 1/4885HDAC2 3/4885
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC3 1/4885HDAC2 3/4885
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC3 1/4885HDAC2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.